Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study
- 537 Downloads
The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an established rheumatoid arthritis (RA) diagnosis] with non-adherence to prescribed subcutaneous biologicals. This paper reports data for the secondary objective from a subset of patients, namely to evaluate non-adherence to prescribed oral antirheumatic drugs in RA patients in Spain using the validated Compliance Questionnaire Rheumatology (CQR). Patients also completed the Morisky–Green Medication Adherence Questionnaire, Beliefs about Medicines Questionnaire, and a questionnaire (developed and validated in Spain) on patient satisfaction with RA treatment and preferences. A total of 271 patients (76.7% females; mean age 55.6 years) were being treated with oral drugs for RA, of which 234 completed the CQR questionnaire. Non-adherence was reported in 49/234 (20.9%) patients. The proportion of non-adherence in younger patients (aged ≤48 years; 37.5%) was double that recorded in patients aged >48 years (p = 0.006). Patients with a perception of lower efficacy also had a higher risk of non-adherence (p = 0.012). Multivariable analysis showed that younger age and male gender were independently associated with risk of non-adherence. There was only slight agreement between the CQR and Morisky–Green assessment tools (kappa coefficient = 0.186), possibly reflecting the fact that both questionnaires measure slightly different aspects of medication adherence. In conclusion, one out of five RA patients was identified as at risk for non-adherence with the CQR, and this was more frequent in younger patients and in males.
KeywordsAdherence Non-adherence Oral medication Questionnaire Rheumatoid arthritis
Study implementation and statistical analysis were conducted by Experior S.L, Spain. Medical writing assistance was provided by David P. Figgitt Ph.D., Content Ed Net, with funding from Merck Sharp & Dohme, Spain. The authors would like to thank the 42 study investigators for their contribution to patient recruitment and data acquisition, and to the patients involved for their collaboration in completing the study questionnaires.
Compliance with ethical standards
Conflict of interest
The ARCO study was financed by Merck Sharp & Dohme, Spain, a subsidiary of Merck & Co, Kenilworth, New Jersey, USA. Yvonne Mestre and Luis Cea-Calvo are full-time employees of Merck Sharp & Dohme (MSD), Spain. The co-authors of the manuscript were also study investigators, and they or their institution received financial compensation for the enrolment of patients in the study. Georgina Salvador has received payments for lectures from BMS, Roche, AbbVie, Amgen, and Pfizer, and for the development of educational presentations from BMS, Roche, Pfizer, AbbVie, and MSD. Juan J. Alegre has received payments as a board member from AbbVie; for consultancy from MSD; for his expert testimony from Roche; for lectures from AbbVie, MSD, Roche, BMS, and Pfizer; for the development of educational presentations from BMS; and his institution has received grants from AbbVie. Ana Ortiz has received payments for grants from the “Instituto de Salud Carlos III”. L. Carmona’s institution (InMusc.) has received consultancy honoraria from MSD. The rest of the authors declare no other conflicts of interest.
- 1.World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Geneva, Switzerland. 2003. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed 25 July 2016
- 3.Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125(9):882.e1–887.e1Google Scholar
- 5.Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2:CD000011Google Scholar
- 6.Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB (2014) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 11:CD000011Google Scholar
- 9.Calvo-Alén J, Monteagudo I, Salvador G et al (2016) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 34:1–8Google Scholar
- 14.Beléndez-Vázquez M, Hernández-Mijares A, Horne R, Weinman J (2007) Evaluación de las creencias sobre el tratamiento: validez y fiabilidad de la versión española del “Beliefs about Medicines Questionnaire” [Assessment of beliefs about treatment: validity and reliability of the Spanish version of the “Beliefs about Medicines Questionnaire”]. Int J Clin Health Psychol 7:767–779 (article in Spanish) Google Scholar
- 15.Carbonell J, Badia X, Grupo EXPRESAR (2006) Desarrollo y validación de un cuestionario de satisfacción con el tratamiento en pacientes con artritis reumatoide. [Development and validation of a satisfaction questionnaire in patients with rheumatoid arthritis]. Reumatol Clin 2(3):137–145 (article in Spanish) CrossRefPubMedGoogle Scholar
- 20.Scheiman-Elazary A, Duan L, Shourt C, Agrawal H, Ellashof D, Cameron-Hay M, Furst DE (2016) The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J Rheumatol 43(3):512–523CrossRefPubMedGoogle Scholar